|
|
|
Products
|
|
| Product N° |
Productname |
Quantity |
Price (EUR) |
Tech sheet |
|
|
YVCACT101A-01
|
Activation Molecule 1 (αβ + γδ T cells), Clone: CACT101A, Mab anti-Bovine,Goat,Sheep
|
0.1 ml.
|
108
|
|
|
|
YVCACT101A-05
|
Activation Molecule 1 (αβ + γδ T cells), Clone: CACT101A, Mab anti-Bovine,Goat,Sheep
|
0.5 ml.
|
342
|
|
|
|
YVCACT26A-01
|
Activation Molecule 2 (predominant reactivity γδ T cells), Clone: CACT26A, Mab anti-Bovine,Goat,Sheep
|
0.1 ml.
|
108
|
|
|
|
YVCACT26A-05
|
Activation Molecule 2 (predominant reactivity γδ T cells), Clone: CACT26A, Mab anti-Bovine,Goat,Sheep
|
0.5 ml.
|
342
|
|
|
|
YVCACT63A-01
|
Activation Molecule 2 (predominant reactivity γδ T cells), Clone: CACT63A, Mab anti-Bovine,Goat
|
0.1 ml.
|
108
|
|
|
|
YVCACT63A-05
|
Activation Molecule 2 (predominant reactivity γδ T cells), Clone: CACT63A, Mab anti-Bovine,Goat
|
0.5 ml.
|
342
|
|
|
|
YVCACT77A-01
|
Activation Molecule 2 (predominant reactivity γδ T cells), Clone: CACT77A, Mab anti-Bovine
|
0.1 ml.
|
108
|
|
|
|
YVCACT77A-05
|
Activation Molecule 2 (predominant reactivity γδ T cells), Clone: CACT77A, Mab anti-Bovine
|
0.5 ml.
|
342
|
|
|
|
YVCACT65A-01
|
Activation Molecule 8 (B cells), Clone: CACT65A, Mab anti-Bovine,Goat,Sheep
|
0.1 ml.
|
108
|
|
|
|
YVCACT65A-05
|
Activation Molecule 8 (B cells), Clone: CACT65A, Mab anti-Bovine,Goat,Sheep
|
0.5 ml.
|
342
|
|
|
|
OBT1305
|
Activation-Induced Cytidine Deaminase (AICDA), AID, CDA2, HIGM2, ~25kD, Goat anti-Human; WB
|
100 µg.
|
30.000
|
|
|
|
ACLPKA312
|
Active Focal Adhesion Kinase, Human, recombinant
|
2 µg.
|
30.000
|
|
|
|
ACLPKA312B
|
Active Focal Adhesion Kinase, Human, recombinant
|
10 µg.
|
30.000
|
|
|
|
BMDV10167
|
Activin Receptor, Type II (actRII), 70kD, Clone: 149/1, Mab anti-Human; WB/IP (denatured)
|
0.5 ml.
|
599
|
|
|
|
YSRTMCA950S
|
Activin, Inhibin Beta A subunit, Clone: E4, Mab anti-Human, Bovine, Swine, Sheep, Horse; frozen/paraffin, IH
|
2 ml.
|
472
|
|
|
|
YSRTMCA950ST
|
Activin, Inhibin Beta A subunit, Clone: E4, Mab anti-Human, Bovine, Swine, Sheep, Horse; frozen/paraffin, IH
|
0.2 ml.
|
146
|
|
|
|
UCBVB168
|
Ac-Trp-Lys-Thr-Phe
|
10 mg.
|
226
|
|
|
|
ACL1ADAM19
|
ADAM-19, Propeptide Domain, Amino terminal, Rabbit anti-Human; WB
|
100 µg.
|
336
|
|
|
|
ACL3ADAM10
|
ADAM-10, MADM, Kuzbanian, Catalytic domain, Rabbit anti-
|
100 µg.
|
336
|
|
|
|
ACLENZ294
|
Acyl-Coenzyme A Dehydrogenase 8, Human, recombinant
|
2 µg.
|
30.000
|
|
|
|
ACL1ADAM15
|
ADAM-15, Metargidin, MDC15, Carboxy terminal, Rabbit anti-Human; WB
|
100 µg.
|
336
|
|
|
|
ACL3ADAM12
|
ADAM-12, Meltrin Alpha, Amino terminal, Rabbit anti-
|
100 µg.
|
336
|
|
|
|
BMAT4660/500
|
ADAM17, TNF-alpha Converting Enzyme (TACE), C-terminal, Rabbit anti-Human, Mouse, Rat; WB
|
500 µg.
|
2.526
|
|
|
|
OBT4183
|
ADAM 10, Rabbit anti-Human; WB
|
0.1 mg.
|
30.000
|
|
|
|
ACL2ADAM10
|
ADAM-10, MADM, Kuzbanian, Amino terminal, Rabbit anti-
|
100 µg.
|
336
|
|
|
|
YSRTAHP586
|
ADAM 10, Rabbit anti-Human
|
0.1 mg.
|
338
|
|
|
|
BMAT4656/500
|
ADAM-10, C-terminal, 732-748aa, Rabbit anti-Human; WB
|
500 µg.
|
2.526
|
|
|
|
BMAT4656/100
|
ADAM-10, C-terminal, 732-748aa, Rabbit anti-Human; WB
|
100 µg.
|
654
|
|
|
|
ACLENZ294B
|
Acyl-Coenzyme A Dehydrogenase 8, Human, recombinant
|
10 µg.
|
30.000
|
|
|
|
ACL2ADAM13
|
ADAM-13, Xenopus, Carboxy terminal, Rabbit anti-
|
100 µg.
|
336
|
|
|
|
ACL1ADAM13
|
ADAM-13, Xenopus, Amino terminal, Rabbit anti-
|
100 µg.
|
336
|
|
|
|
ACL2ADAM15
|
ADAM-15, Metargidin, MDC15, Amino terminal, Rabbit anti-Human; WB
|
100 µg.
|
336
|
|
|
|
ACL1ADAM20
|
ADAM-20, Carboxy terminal, Rabbit anti-Human
|
100 µg.
|
336
|
|
|
|
ACL2ADAM12
|
ADAM-12, Meltrin Alpha, Carboxy terminal, Long form, Rabbit anti-Human; WB
|
100 µg.
|
336
|
|
|
|
YNNE163PAb
|
Acylase, Rabbit anti-Swine kidney
|
1 mg.
|
697
|
|
|
|
ACL3ADAM17P
|
ADAM-17, TACE (TNF-a Converting Enzyme), Carboxy terminal, Peptide
|
100 µg.
|
30.000
|
|
|
|
ACL4ADAM10
|
ADAM-10, MADM, Kuzbanian, Amino terminal, Rabbit anti-
|
100 µg.
|
336
|
|
|
|
ACL1ADAM12
|
ADAM-12, Meltrin Alpha, Amino terminal, Rabbit anti-
|
100 µg.
|
336
|
|
|
|
YSRTAHP816GA
|
ADAM-15, Rabbit anti-; WB
|
0.1 mg.
|
680
|
|
|
|
ACL3ADAM17
|
ADAM-17, TACE (TNF-a Converting Enzyme), Carboxy terminal, Rabbit anti-Human
|
100 µg.
|
336
|
|
|
|
ACL2ADAM20
|
ADAM-20, Amino terminal, Rabbit anti-
|
100 µg.
|
336
|
|
|
|
ACL3ADAM20
|
ADAM-20, Carboxy end Propeptide domain, Rabbit anti-Human
|
100 µg.
|
336
|
|
|
|
ACL3ADAM19
|
ADAM-19, Meltrin beta, Catalytic domain, Rabbit anti-Human
|
100 µg.
|
336
|
|
|
|
ACL2ADAM19
|
ADAM-19, Meltrin beta, Carboxy terminal, Rabbit anti-Human; WB
|
100 µg.
|
336
|
|
|
|
ACL2ADAM17
|
ADAM-17, TACE (TNF-a Converting Enzyme), Amino terminal, Rabbit anti-Human, Swine, Rat; WB
|
100 µg.
|
336
|
|
|
|
BMAT4660/100
|
ADAM17, TNF-alpha Converting Enzyme (TACE), C-terminal, Rabbit anti-Human, Mouse, Rat; WB
|
100 µg.
|
654
|
|
|
|
ACL3ADAM15
|
ADAM-15, Metargidin, MDC15, Catalytic domain, Rabbit anti-
|
100 µg.
|
336
|
|
|
|
ACL1ADAM10
|
ADAM-10, MADM, Kuzbanian (Kuz), Carboxy terminal, Latent & Active forms, Rabbit anti-Human; WB
|
100 µg.
|
336
|
|
|
|
ACL2ADAM21H
|
ADAM-21, Amino terminal, Catalytic domain, Rabbit anti-Human
|
100 µg.
|
336
|
|
|
|
ACL4ADAM17
|
ADAM-17, TACE (TNF-a Converting Enzyme), Catalytic Domain, Rabbit anti-Human
|
100 µg.
|
336
|
|
|
|
|
|
|